Published in J Exp Med on April 20, 1998
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med (2008) 7.80
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 4.79
New paths in human cancer serology. J Exp Med (1998) 3.12
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 2.90
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. Proc Natl Acad Sci U S A (2004) 2.80
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
A simplified immunoprecipitation method for quantitatively measuring antibody responses in clinical sera samples by using mammalian-produced Renilla luciferase-antigen fusion proteins. BMC Biotechnol (2005) 2.41
De novo induction of a cancer/testis antigen by 5-aza-2'-deoxycytidine augments adoptive immunotherapy in a murine tumor model. Cancer Res (2006) 2.27
The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res (2005) 2.22
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci U S A (2007) 2.19
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Proc Natl Acad Sci U S A (2006) 2.19
PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J Immunol (2009) 2.12
Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci U S A (1998) 2.11
Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A (2003) 2.09
Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med (2002) 2.07
Tumor immunity and autoimmunity induced by immunization with homologous DNA. J Clin Invest (1998) 2.02
CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A (2001) 1.96
Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol (2001) 1.89
An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A (2001) 1.85
Autoantibodies as reporters identifying aberrant cellular mechanisms in tumorigenesis. J Clin Invest (2001) 1.81
Antibody response to DBY minor histocompatibility antigen is induced after allogeneic stem cell transplantation and in healthy female donors. Blood (2003) 1.79
Protein microarray signature of autoantibody biomarkers for the early detection of breast cancer. J Proteome Res (2010) 1.75
A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother (2009) 1.75
Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma. J Exp Med (2000) 1.67
Yeast homolog of a cancer-testis antigen defines a new transcription complex. EMBO J (2006) 1.58
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies. Ann Rheum Dis (2001) 1.55
Occurrence of autoantibodies to annexin I, 14-3-3 theta and LAMR1 in prediagnostic lung cancer sera. J Clin Oncol (2008) 1.55
Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol (2000) 1.52
Aberrant expression of fetal RNA-binding protein p62 in liver cancer and liver cirrhosis. Am J Pathol (2001) 1.49
Autoimmunity and the immunotherapy of cancer: targeting the "self" to destroy the "other". Crit Rev Immunol (2000) 1.47
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations. Proc Natl Acad Sci U S A (2002) 1.38
Strategy for monitoring T cell responses to NY-ESO-1 in patients with any HLA class I allele. Proc Natl Acad Sci U S A (2000) 1.36
Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest (2002) 1.36
Antitumor immunity and cancer stem cells. Ann N Y Acad Sci (2009) 1.36
Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother (2004) 1.34
T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun (2007) 1.34
Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J Immunother (2008) 1.32
Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics (2006) 1.32
CML66, a broadly immunogenic tumor antigen, elicits a humoral immune response associated with remission of chronic myelogenous leukemia. Proc Natl Acad Sci U S A (2001) 1.30
Multiple cancer/testis antigens are preferentially expressed in hormone-receptor negative and high-grade breast cancers. PLoS One (2011) 1.29
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer. Cancer Immun (2007) 1.28
Regulation of cancer germline antigen gene expression: implications for cancer immunotherapy. Future Oncol (2010) 1.25
PAGE-1, an X chromosome-linked GAGE-like gene that is expressed in normal and neoplastic prostate, testis, and uterus. Proc Natl Acad Sci U S A (1998) 1.24
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn (2010) 1.23
NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses. Blood (2005) 1.19
Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas. J Clin Invest (2003) 1.17
Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy. J Immunol (2002) 1.16
De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol (2001) 1.15
Tumours can act as adjuvants for humoral immunity. Immunology (2001) 1.14
Using protein microarray as a diagnostic assay for non-small cell lung cancer. Am J Respir Crit Care Med (2005) 1.13
Immunomic analysis of human sarcoma. Proc Natl Acad Sci U S A (2003) 1.11
CD8(+) T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients. Proc Natl Acad Sci U S A (2002) 1.11
The SSX family of cancer-testis antigens as target proteins for tumor therapy. Clin Dev Immunol (2010) 1.06
Developing recombinant and synthetic vaccines for the treatment of melanoma. Curr Opin Oncol (1999) 1.06
Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res (2011) 1.06
Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep (2012) 1.05
Aberrant expression of homeobox gene HOXA7 is associated with müllerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response. Proc Natl Acad Sci U S A (2001) 1.05
Immunological ignorance of solid tumors. Springer Semin Immunopathol (2005) 1.05
Identification of proacrosin binding protein sp32 precursor as a human cancer/testis antigen. Proc Natl Acad Sci U S A (2001) 1.04
NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens. Br J Cancer (2000) 1.01
Physical characterization of the "immunosignaturing effect". Mol Cell Proteomics (2012) 1.00
Mini-array of multiple tumor-associated antigens to enhance autoantibody detection for immunodiagnosis of hepatocellular carcinoma. Autoimmun Rev (2006) 1.00
IFN-gamma enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation. Proc Natl Acad Sci U S A (2004) 1.00
Tumor-associated autoantibodies as diagnostic and prognostic biomarkers. BMB Rep (2012) 0.99
A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer. J Transl Med (2013) 0.99
CML28 is a broadly immunogenic antigen, which is overexpressed in tumor cells. Cancer Res (2002) 0.98
Protein biomarkers for the early detection of breast cancer. Int J Proteomics (2011) 0.98
A novel multiplex assay combining autoantibodies plus PSA has potential implications for classification of prostate cancer from non-malignant cases. J Transl Med (2011) 0.98
A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma. Sarcoma (2013) 0.98
Clinical proteomics: present and future prospects. Clin Biochem Rev (2006) 0.97
Autoantibodies to tumor-associated antigens as biomarkers in cancer immunodiagnosis. Autoimmun Rev (2010) 0.97
Comparison of candidate serologic markers for type I and type II ovarian cancer. Gynecol Oncol (2011) 0.97
Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One (2014) 0.96
Antigen-specific immunotherapy of cervical and ovarian cancer. Immunol Rev (2008) 0.96
Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity. Front Immunol (2015) 0.96
NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS One (2012) 0.94
Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer (2010) 0.94
A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature. Oncogene (2012) 0.92
Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One (2011) 0.92
Tumor vaccines for breast cancer. Cancer Invest (2009) 0.91
Stem cells and targeted approaches to melanoma cure. Mol Aspects Med (2013) 0.90
Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapy. PLoS One (2011) 0.90
Sp17 gene expression in myeloma cells is regulated by promoter methylation. Br J Cancer (2004) 0.90
An immunodominant SSX-2-derived epitope recognized by CD4+ T cells in association with HLA-DR. J Clin Invest (2004) 0.90
Lung cancer-associated auto-antibodies measured using seven amino acid peptides in a diagnostic blood test for lung cancer. Cancer Biol Ther (2010) 0.89
Identification of a Specific Vimentin Isoform That Induces an Antibody Response in Pancreatic Cancer. Biomark Insights (2006) 0.89
The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray. Electrophoresis (2009) 0.89
Analysis of the B cell repertoire against autoantigens in patients with giant cell arteritis and polymyalgia rheumatica. Clin Exp Immunol (2002) 0.89
NY-ESO-1 antibody as a novel tumour marker of gastric cancer. Br J Cancer (2013) 0.88
Prevalence of antitumor antibodies in laying hen model of human ovarian cancer. Int J Gynecol Cancer (2009) 0.88
DNA methylation: its role in cancer development and therapy. Curr Probl Cancer (2008) 0.88
Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother (2012) 0.88
Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients. J Transl Med (2013) 0.87
Characterization of a cancer/testis (CT) antigen gene family capable of eliciting humoral response in cancer patients. Proc Natl Acad Sci U S A (2006) 0.87
Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol (2004) 0.86
Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC). Exp Hematol Oncol (2013) 0.85
Autoantibodies targeting tumor-associated antigens in metastatic cancer: Sialylated IgGs as candidate anti-inflammatory antibodies. Oncoimmunology (2013) 0.84
Analysis of the expression of human tumor antigens in ovarian cancer tissues. Cancer Biomark (2010) 0.84
Multiplexed Serum Biomarkers for the Detection of Lung Cancer. EBioMedicine (2016) 0.84
Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A (1979) 365.71
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1993) 6.47
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (1995) 5.46
A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med (1994) 5.03
Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A (1995) 4.89
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Isolation and sequence of a cDNA clone for human tyrosinase that maps at the mouse c-albino locus. Proc Natl Acad Sci U S A (1987) 4.49
Human tumor antigens recognized by T lymphocytes. J Exp Med (1996) 3.63
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res (1981) 3.62
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res (1994) 2.74
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer (1995) 2.28
The SSX-2 gene, which is involved in the t(X;18) translocation of synovial sarcomas, codes for the human tumor antigen HOM-MEL-40. Cancer Res (1996) 1.93
Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today (1997) 1.91
Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens. Int J Cancer (1996) 1.75
Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst (1996) 1.72
Identification of the MAGE-1 gene product by monoclonal and polyclonal antibodies. Proc Natl Acad Sci U S A (1994) 1.61
Immunity to oncogenic proteins. Immunol Rev (1995) 1.58
Analysis of the anti-p53 antibody response in cancer patients. Cancer Res (1993) 1.49
Immunophenotyping of melanomas for tyrosinase: implications for vaccine development. Proc Natl Acad Sci U S A (1995) 1.48
Characterization of the antibody response specific for the human endogenous retrovirus HTDV/HERV-K. J Virol (1997) 1.37
Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer (1995) 1.37
Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci U S A (1996) 1.32
Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma Res (1996) 1.16
Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol (1996) 1.16
Melanoma patients immunized with melanoma cell vaccine induce antibody responses to recombinant MAGE-1 antigen. J Immunol (1995) 1.02
Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine. Proc Natl Acad Sci U S A (1995) 0.95
An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1975) 23.42
A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 14.57
A new class of murine leukemia virus associated with development of spontaneous lymphomas. Proc Natl Acad Sci U S A (1977) 13.96
IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature (2001) 11.03
Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature (1994) 10.34
Tumor necrosis factor (TNF). Science (1985) 8.80
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol (2000) 8.08
Ly-A and Ly-B: two systems of lymphocyte isoantigens in the mouse. Proc R Soc Lond B Biol Sci (1968) 7.51
Expression of T-cell differentiation antigens on effector cells in cell-mediated cytotoxicity in vitro. Evidence for functional heterogeneity related to the surface phenotype of T cells. J Exp Med (1975) 7.20
Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse. Proc Natl Acad Sci U S A (1979) 6.93
Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A (1976) 6.82
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A (1997) 6.67
Antigens of leukemias induced by naturally occurring murine leukemia virus: their relation to the antigens of gross virus and other murine leukemia viruses. J Exp Med (1966) 6.45
Characterization of two 85 kd proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3-kinase. Cell (1991) 6.28
The G (Gross) leukemia antigen. Cancer Res (1965) 6.07
The G-IX system. A cell surface allo-antigen associated with murine leukemia virus; implications regarding chromosomal integration of the viral genome. J Exp Med (1971) 6.06
Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology (2006) 5.67
Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell (1992) 5.29
Surface alloantigens of plasma cells. J Exp Med (1970) 5.19
Mechanisms of epithelial cell-cell adhesion and cell compaction revealed by high-resolution tracking of E-cadherin-green fluorescent protein. J Cell Biol (1998) 5.03
Cell surface antigens of human malignant melanoma: definition of six antigenic systems with mouse monoclonal antibodies. Proc Natl Acad Sci U S A (1980) 4.66
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med (1998) 4.65
Antigenic modulation. Loss of TL antigen from cells exposed to TL antibody. Study of the phenomenon in vitro. J Exp Med (1968) 4.63
Changes in expression of murine leukemia virus antigens and production of xenotropic virus in the late preleukemic period in AKR mice. Proc Natl Acad Sci U S A (1976) 4.52
Cytotoxic T cells: Lyt phenotype and blocking of killing activity by Lyt antisera. Proc Natl Acad Sci U S A (1979) 4.14
Characterization of tumor necrosis factor-deficient mice. Proc Natl Acad Sci U S A (1997) 4.10
Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci U S A (1978) 3.99
Current enigmas in cancer research. Harvey Lect (1973) 3.91
Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci U S A (1983) 3.83
p53 transformation-related protein: detection by monoclonal antibody in mouse and human cells. Proc Natl Acad Sci U S A (1981) 3.72
Cancer immunology: the search for specificity--G. H. A. Clowes Memorial lecture. Cancer Res (1981) 3.62
Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med (2001) 3.60
Glycogen storage disease in adults. Ann Intern Med (1994) 3.58
Microinjection of monoclonal antibody to protein p53 inhibits serum-induced DNA synthesis in 3T3 cells. Proc Natl Acad Sci U S A (1982) 3.58
Antigenic structure of cell surfaces. An immunoferritin study of the occurrence and topography of H-2' theta, and TL alloantigens on mouse cells. J Exp Med (1969) 3.53
Immunoglobulin and other surface antigens of cells of the immune system. J Exp Med (1971) 3.50
An approach to the mapping of antigens on the cell surface. Proc Natl Acad Sci U S A (1968) 3.46
Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med (1979) 3.43
Antigens of tumors and leukemias induced by viruses. Fed Proc (1966) 3.43
Cell surface antigens of human malignant melanoma. III. Recognition of autoantibodies with unusual characteristics. J Exp Med (1977) 3.42
Distinct specificity in the recognition of phosphoinositides by the pleckstrin homology domains of dynamin and Bruton's tyrosine kinase. EMBO J (1996) 3.41
PI 3-kinase is a dual specificity enzyme: autoregulation by an intrinsic protein-serine kinase activity. EMBO J (1994) 3.39
Genetic linkage relationships of loci specifying differentiation alloantigens in the mouse. Transplantation (1972) 3.34
Phospholipase D: a downstream effector of ARF in granulocytes. Science (1994) 3.33
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med (1982) 3.27
Modification of the antigenic structure of the cell membrane by thymus-leukemia (TL) antibody. Proc Natl Acad Sci U S A (1967) 3.26
Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity (1994) 3.24
Isolation and some characteristics of a group-specific antigen of the murine leukemia viruses. Virology (1969) 3.21
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 3.19
New paths in human cancer serology. J Exp Med (1998) 3.12
PI 3-kinase: structural and functional analysis of intersubunit interactions. EMBO J (1994) 3.02
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. Proc Natl Acad Sci U S A (2000) 3.00
Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease. J Pediatr (2006) 2.97
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues. Int J Cancer (2001) 2.95
Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci U S A (1986) 2.94
Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci U S A (1990) 2.91
A recessive contiguous gene deletion causing infantile hyperinsulinism, enteropathy and deafness identifies the Usher type 1C gene. Nat Genet (2000) 2.87
Mouse isoantigens: separation of soluble TL (thymus-leukemia) antigen from soluble H-2 histocompatibility antigen by column chromatography. J Exp Med (1967) 2.86
Shared viral antigen of mammalian leukaemia viruses. Nature (1970) 2.84
Eradication of established tumors by CD8+ T cell adoptive immunotherapy. Immunity (2000) 2.81
Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. Proc Natl Acad Sci U S A (2000) 2.79
G (Gross) and H-2 cell-surface antigens: location on Gross leukemia cells by electron microscopy with visually labeled antibody. Proc Natl Acad Sci U S A (1970) 2.77
GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med (1982) 2.74
Predictors of readmission among elderly survivors of admission with heart failure. Am Heart J (2000) 2.71
Immunogenetics of cell surface antigens of mouse leukemia. Annu Rev Genet (1977) 2.69
Use of hybrid antibody with anti-gamma-G and anti-ferritin specificities in locating cell surface antigens by electron microscopy. J Exp Med (1968) 2.62
Stability increase of the lumbar spine with different muscle groups. A biomechanical in vitro study. Spine (Phila Pa 1976) (1995) 2.62
Detection of antibody to autologous human leukemia cells by immune adherence assays. Proc Natl Acad Sci U S A (1977) 2.59
Occurrence of natural antibody to the G (gross) leukemia antigen in mice. Cancer Res (1966) 2.57
T-cell-mediated cytotoxicity against autologous malignant melanoma: analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A (1984) 2.54
Thymus cells of radiation-chimeras: TL phenotype, sensitivity to guinea-pig serum, and origin from donor cells. Nature (1965) 2.54
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens. J Exp Med (1981) 2.53
Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci U S A (1999) 2.53
Leukemia-associated transplantation antigens related to murine leukemia virus. The X.1 system: immune response controlled by a locus linked to H-2. J Exp Med (1973) 2.52
Production of stable cytolytic T-cell clones directed against autologous human melanoma. Int J Cancer (1987) 2.50
Serologically demonstrable alloantigens of mouse epidermal cells. J Exp Med (1972) 2.48
Effect of tumour necrosis factor on cultured human melanoma cells. Nature (1975) 2.46
Factors affecting synthesis of ascorbic acid in cress seedlings. 2. Ascorbic acid synthesis in relation to sugar formation. Biochem J (1949) 2.46
Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc Natl Acad Sci U S A (1994) 2.44
Partial purification of a serum factor that causes necrosis of tumors. Proc Natl Acad Sci U S A (1976) 2.42
Horizontal transmission of feline leukaemia virus. Nature (1973) 2.34
Phosphatidylinositol-3,4,5-trisphosphate (PtdIns-3,4,5-P3)/Tec kinase-dependent calcium signaling pathway: a target for SHIP-mediated inhibitory signals. EMBO J (1998) 2.29
Group-specific viral antigens in the milk and tissues of mice naturally infected with mammary tumor virus or Gross leukemia virus. Virology (1968) 2.26